A MP-activated protein kinase (AMPK) integrates signals related to energy expenditure and energy production to regulate cellular metabolic processes. In response to metabolic stress, AMPK is rapidly activated to preserve energy homeostasis. AMPK is involved in the hypertrophic response to hemodynamic overload 1 and both AMPKα1 and AMPKα2 activities are elevated in response to pressure overload in rats. 2 AMPK activity is also increased in pacing-induced heart failure in dogs.
A MP-activated protein kinase (AMPK) integrates signals related to energy expenditure and energy production to regulate cellular metabolic processes. In response to metabolic stress, AMPK is rapidly activated to preserve energy homeostasis. AMPK is involved in the hypertrophic response to hemodynamic overload 1 and both AMPKα1 and AMPKα2 activities are elevated in response to pressure overload in rats. 2 AMPK activity is also increased in pacing-induced heart failure in dogs. 3 Using AMPKα2-deficient mice, we previously demonstrated that AMPKα2 protects against transverse aortic constriction (TAC)-induced ventricular hypertrophy and dysfunction, in part, by repressing mammalian target of rapamycin (mTOR) signaling. 1 Recently, we found that AMPKα2 plays an important role in regulating the expression of myocardial estrogen-related receptor α (ERRα) (and its downstream mitochondrial enzymes), 4 an important transcriptional factor related to heart failure development. Most recently, we demonstrated that AMPKα2 reduces cardiomyocyte microtubule proliferation, a cytoskeletal abnormality often associated with the development of heart failure. 5 Taken together, these observations suggest an important role for AMPKα2 in favorable adaptations of the heart in response to stress. However, the impact of AMPKα1 on ventricular structure and function under stress conditions remains unclear.
Metformin, a drug with insulin-sensitizing properties, is used widely in patients with diabetes mellitus and is known to activate AMPK. In large-scale clinical trials of patients with diabetes mellitus, metformin decreases the long-term risk of cardiovascular death and nonfatal myocardial infarction. 6, 7 Metformin has also been shown to attenuate the degree of heart failure in dogs in response to rapid ventricular pacing, 3 reduce the degree of hypertrophy and fibrosis in mice subjected to a chronic pressure overload, 8 and preserve left ventricular (LV) function and survival in mice after myocardial infarction. 9 Because AMPKα2 protects against pressure overload-induced LV hypertrophy and heart failure, we tested the hypothesis that metformin exerts its protective effect through activation of AMPKα2. To our surprise, we found that metformin was equally effective in attenuating TAC-induced LV hypertrophy and dysfunction in both wild-type and AMPKα2
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gene knockout mice, indicating that metformin can protect the heart in response to chronic pressure overload through an AMPKα2-independent pathway. We also found that AMPKα1 knockout had no detectable effect on LV structure and function in mice in response to TAC.
Materials and Methods
An extended Materials and Methods section can be found in the online-only Data Supplement.
Animals and Experimental Protocol
All animal studies were performed according to a protocol approved by the University of Minnesota Institutional Animal Care and Use Committee. Adult (12-15 weeks) male AMPKα1 knockout mice (mixed background of C57B6J and 129) and AMPKα2 knockout mice (background of C57B6J) 10, 11 and their wild-type littermates were used in this study. TAC was performed as previously described. 12 To avoid the unwanted influence of cardiac death occurring shortly after the TAC procedure, 13 mice were assigned randomly to 2 groups 3 days after TAC and then treated with either metformin (100 mg/kg per day, gavage) or vehicle for 3 weeks. Echocardiography and hemodynamic measurements were performed during anesthesia with 1.5% isoflurane.
Statistical Analysis
Results are expressed as mean±SE of the mean. For the study of TAC-induced LV hypertrophy and dysfunction, 2-way ANOVA was used to test each variable for differences among the treatment groups. If the ANOVA demonstrated a significant effect, post hoc comparisons were made pairwise using Fisher least significant difference test. A P value ≤0.05 was considered significantly different.
Results
AMPKα2 but Not AMPKα1 Protected the Heart From TAC-Induced LV Hypertrophy and Heart Failure Consistent with our previous observation, 1 AMPKα2 knockout had no effect on LV weight, lung weight, and LV ejection fraction under control conditions but significantly exacerbated TAC-induced LV hypertrophy, pulmonary congestion, and LV dysfunction ( Figure S1 , Table S3, and Table S4 in the onlineonly Data Supplement). Western blots showed that AMPKα2 knockout also caused significant reductions of the protein expressions of myocardial ERRα and its downstream targets medium-chain acyl-CoA dehydrogenase (MCAD), carnitine palmitoyl transferase 1b (CPT1b), cluster of differentiation 36 (CD36), fatty acid transport protein 1 (FATP1), cytochrome C oxidase subunit-3, cytochrome C, and uncoupling protein 3 (UCP3) under control conditions or after TAC ( Figure S2 ). AMPKα2 knockout also significantly reduced mRNAs of ERRα and its downstream target genes ( Figure S3) . Interestingly, AMPKα1 knockout had no detectable effect on LV weight, the ratio of LV weight to body weight or to tibia length, or LV function either under basal conditions or after TAC ( Figure S4 and Table S5 ). Thus, after 3 weeks of TAC, the ratio of LV weight to tibia length and the ratio of lung weight to tibia length were increased to a similar extent in both wildtype and AMPKα1 knockout mice. The degree of LV dilation and dysfunction in the AMPKα1 knockout mice exposed to TAC was also comparable with those in the wild-type littermates ( Figure S4 and Table S6 ). The heart rates were similar between wild-type and AMPKα1 knockout mice under control conditions and after TAC (Table S6 ). After TAC, LV dp/dt max , LVdP/dt min , and systolic aortic pressure (proximal to the TAC site) were not different between wild-type and AMPKα1 knockout mice (Table S7 ). AMPKα2 expression was not altered in the AMPKα1 knockout mice under control conditions ( Figure  S5 ). Myocardial AMPKα1 expression was increased significantly in wild-type mice after TAC, whereas AMPKα2 expression was reduced significantly in the AMPKα1 knockout mice after TAC ( Figure S5 ). In addition, AMPKα1 knockout had no detectable effect on expression of cardiac ERRα and its downstream targets (such as MCAD, CPT1b, CD36, FATP1, cytochrome C oxidase 3, cytochrome C, and UCP3) under control conditions or after TAC ( Figure S6 ).
Metformin Attenuated TAC-Induced LV Hypertrophy and Heart Failure in Wild-Type Mice
To study the cardioprotective effect of metformin, we treated TAC-operated wild-type mice with metformin or vehicle (normal saline) for 3 weeks. Under control conditions, metformin had no detectable effect on LV mass, structure, and function (Tables S8 and S9 ). TAC caused significant increases of LV weight, lung weight, and their ratio to body weight ( Figure 1) . TAC also caused a significant decrease in LV fractional shorting and a significant increase in LV end-systolic and end-diastolic diameters ( Figure 1D and 1E). Metformin significantly attenuated the TAC-induced LV hypertrophy, increase of lung weight, decrease of LV ejection fraction, and increase of LV end-diastolic and end-systolic diameters as shown in Figure 1 and Table S10 . Based on histological analysis, metformin did not affect the TAC-induced increase of LV fibrosis ( Figure S7 ), indicating that the reduced LV 
Metformin Attenuated TAC-Induced LV Hypertrophy and Dysfunction in AMPKα2 Knockout Mice
To further investigate the possible mechanism underlying the cardioprotective effect of metformin, we treated sham or TAC-operated AMPKα2 knockout mice with metformin or with vehicle for 3 weeks. Under control conditions, metformin had no detectable effect on LV mass, structure, and function ( Figure 4 ; Table S11 ). Metformin significantly attenuated the TAC-induced increase in LV weight, lung weight, and their ratios to body weight and tibia length ( Figure 4 ; Table S11 ). Metformin also significantly attenuated the TAC-induced decrease of LV fractional shortening and the increase of LV end-diastolic and end-systolic diameters ( Figure 4 ). Metformin did not affect TAC-induced LV fibrosis in AMPKα2 knockout mice ( Figure S9 ). Metformin also significantly attenuated the TAC-induced increases of myocardial ANP and 4-HNE in AMPKα2 knockout mice ( Figure 5 ; Figure S10 ). These results indicate that metformin effectively attenuates TAC-induced LV hypertrophy and dysfunction in AMPKα2 knockout mice ( Figure S11 ).
Metformin Attenuated TAC-Induced mTOR Activation in AMPK α2 Knockout Mice
Under sham conditions, metformin treatment significantly increased myocardial p-AMPK Thr172 and p-ACC
Ser79
, indicating increased activation of AMPKα1. However, this increase was not significantly different from the slightly elevated levels of , total mTOR (t-mTOR), p-p70S6 kinase 
Discussion
The present study reveals 2 major new findings. First, we demonstrated that the AMPK activator metformin was effective in attenuating TAC-induced LV hypertrophy and heart failure in both wild-type and AMPKα2 knockout mice, indicating that metformin protects mice from chronic pressure overload, in part, through an AMPKα2-independent molecular pathway. Second, we demonstrated that AMPKα1 knockout has no detectable effect on LV structure and function in mice either under control conditions or after TAC. Our current study supports the notion that AMPKα1 and AMPKα2 exert different physiological and pathological functions in the heart. The findings that only AMPKα2 knockout significantly reduced the expressions of myocardial ERRα and its downstream targets, such as MCAD, CPT1b, CD36, FATP1, cytochorome C oxidase subunit-3, cytochrome C, UCP3, and SOD2 under both control conditions and after TAC, demonstrate that AMPKα2 is more important than AMPKα1 in maintaining normal LV structure and function. The differences in the influence of AMPKα2 and AMPKα1 on the cardiac adaptation to stress may relate to their different contributions to overall myocardial AMPK activity (AMPKα2 is the dominant isoform in mouse heart), their different cellular distribution (AMPKα2 is mainly expressed in cardiomyoyctes, whereas AMPKα1 is more abundant in other cell types), and their variable subcellular distribution (AMPKα2 is distributed in both nucleus and cytosol, whereas AMPKα1 is expressed only in cytosol). A recent study demonstrated that AMPKα1 contributes >80% of total AMPK activity, whereas AMPKα2 contributes ≈20% of total AMPK activity in the mouse aorta. However, deletion of AMPKα2 but not AMPKα1 exacerbated neointima formation in mice.
14 A study from the same group further demonstrated that activation of AMPKα2 but not AMPKα1 contributed to the nicotine-induced formation of abdominal aortic aneurysms in mice in vivo. 15 Thus, different cellular and subcellular distribution or protein interactions of AMPKα2 and AMPKα1 likely contribute to their different cardiac protective effects.
The UK Prospective Diabetes Study has shown that metformin decreased the risk of cardiovascular death and the incidence of myocardial infarction associated with diabetes mellitus. 16 Additional clinical studies have demonstrated that metformin decreased the risk of all-cause mortality and cardiovascular death in patients with type-2 diabetes mellitus. 6, 7 Eurich et al 17 reported the results of a meta-analysis showing that metformin was the only antidiabetic agent to reduce allcause mortality without causing any harm in patients who had heart failure and diabetes mellitus. Moreover, metformin attenuated rapid ventricular pacing-induced heart failure in dogs and pressure overload-induced LV hypertrophy in mice. 3, 8, 18 Thus, our finding that metformin attenuated TAC-induced LV hypertrophy and dysfunction in mice is fully anticipated. , and p-S6 ser235 in both wild-type and AMPKα2 knockout mice suggest that metformin can attenuate myocardial mTOR signaling independent of AMPKα2 activation. mTOR signaling promotes ventricular hypertrophy, whereas inhibition of mTOR signaling attenuates ventricular hypertrophy. Thus, metformin attenuation of myocardial p-mTOR ser2448 , p-p70S6K
Thr389
, and p-S6 ser235 in both wild-type and AMPKα2 knockout mice may help to explain its antihypertrophic effects. As metformin did not affect blood glucose in these nondiabetic mice, the beneficial effect of metformin is likely independent of its effect on blood glucose.
We demonstrated that metformin effectively attenuated the TAC-induced increase of LV weight, lung weight, and their ratios to body weight in both wild-type and AMPKα2 knockout mice. Metformin also significantly improved LV fractional shortening, attenuated LV dilation, and limited expression of myocardial ANP in both wild-type and AMPKα2 knockout mice exposed to TAC. These data indicate that metformin can exert cardiac protective effects through an AMPKα2 independent molecular pathway. Our findings differ from a previous report that metformin attenuation of LV hypertrophy is dependent on AMPKα2. 18 A study from the same group reported that metformin attenuated LV fibrosis in mice, 8 a result that is also at variance with our observation. These discrepancies may be the result of technical differences between the studies. Thus, the degree of pressure overload and ventricular hypertrophy produced by TAC was considerably different between studies. Fu et al 18 reported a 26% increase in ventricular weight in the vehicle-treated AMPKα2 knockout mice, as compared with a 58% increase in ventricular mass in the vehicle-treated AMPKα2 knockout mice in the present study. In addition, the difference in genetic backgrounds of the AMPKα2 knockout mice (a 129/C57B6 mixed background for AMPKα2 knockout mice was used by Fu et al 18 versus a C57B6J background for the AMPKα2 knockout mice in the present study) could have contributed to the differing results.
Several studies have demonstrated that metformin exerts some biological and physiological effects through AMPK-independent molecular pathways, and these effects may also influence cardiac hypertrophy. A previous study demonstrated that metformin inhibits hepatic gluconeogenesis in an AMPK-independent manner via a decrease in hepatic energy state. 19, 20 There is also indirect evidence that metformin can increase adenosine production in the heart. 21 Adenosine protects against pressure overload hypertrophy and heart failure and, like AMPK activation, also attenuates mTOR signaling. 22, 23 In addition, metformin has been shown to decrease mTOR signaling independent of AMPK through either activation of RAG2 GTPase 24 or through activation of protein regulated in development and DNA damage response 1 (REDD; also known as DDIT4). 25 It is possible that RAG2 or REDD also plays a role in the metformin attenuation of cardiac mTOR signaling and hypertrophy observed in AMPKα2 knockout mice. Additional studies have demonstrated that metformin alters Stat3 activity independent of AMPK. 26 There is evidence that Stat3 plays a role in promoting cardiac hypertrophy, 27 so Stat3 suppression may also play a role in the antihypertrophic effects of metformin. The extent to which these actions of metformin attenuate cardiac hypertrophy independent of AMPKα2 is not clear.
AMPKα1 knockout had no observable influence on TAC-induced hypertrophy and heart failure; however, because AMPKα1 is still expressed in AMPKα2 knockout mice, we cannot exclude the possibility that metformin might exert its cardiac protective effect through a slight compensatory increase in the activation of AMPKα1. Another limitation of the present study is that because AMPKα1 knockout and AMPKα2 knockout mice are global knockout strains, the phenotypes observed in these knockout mice may not be because of effects on cardiomyocytes or myocardial tissues alone. Similarly, metformin may have effects on multiple organ systems or other cell types that also contribute to its beneficial effects in attenuating TACinduced LV hypertrophy and heart failure.
Perspectives
Although metformin is a known activator of AMPK, it is unclear whether its cardioprotection acts through an AMPKα2-dependent pathway. We demonstrated that metformin attenuates pressure overload-induced heart failure through an AMPKα2-independent mechanism. We also demonstrated that AMPKα1 plays a negligible role in protecting the heart against heart failure development.
Sources of Funding
This study was supported by US Public Health Service Grants HL098669, HL098719, HL102597, HL089249, HL021872, and R01HL105406 from the National Institutes of Health, and grant Transverse aortic constriction (TAC) was performed as previously described. 1 For the metformin study, 3 days after TAC, the mice were randomly assigned to two groups treated with either metformin (100mg/kg/day, gavage) or vehicle for 3 weeks. Three weeks post surgery, echocardiography and hemodynamic measurements were performed during mild anesthesia (1.5% isoflurane by inhalation).
Echocardiography. Mouse echocardiographic images were obtained with a Visualsonics high resolution 770 system as previously described.
Western Blots and Quantitative Real-time PCR.
Whole cell lysate from heart tissue or cardiomyocytes was resolved on SDS-PAGE gel and transferred to PVDF membrane (Amersham Biosciences). Primary antibodies against AMPKα1, AMPKα2, COX-3, and GAPDH are from Santa Cruz Biotech; antibodies against p-AMPK Thr172 , p-ACC Ser79 , and cytochrome C are from Cell Signaling; antibody against CPT-1b is from Alpha Diagnostics; antibody against MCAD is from Cayman Chemical; ERRα antibody is from Millipore Bioscience; antibodies against actin and UCP3 are from Sigma. HRP conjugated secondary antibodies were from BioRad Laboratories and Sigma, and were detected by enhanced chemiluminescence (Amersham Biosciences).
For RT and quantitative real-time PCR, total RNA was reverse-transcribed using the HighCapacity cDNA Reverse Transcription Kit from Applied Biosystems. The real-time PCR reaction was performed using the 7900HT Fast Real-Time PCR System from Applied Biosystems. Primers used for amplification are listed in Supplemental Table S1 . Results were normalized to GAPDH levels.
Histological Staining and Measurement of Fibrosis.
Tissue sections (6 µm) from the central portion of the LV were stained with Sirius red (Sigma, St Louis, Mo) for fibrosis.
Statistical Analysis.
Results are expressed as means ± standard error of the mean. Number of samples in each group for each experiment is at least six, or is indicated in the legend. For the study of TAC-induced LV hypertrophy and dysfunction, two-way analysis of variance (ANOVA) was used to test each variable for differences among the treatment groups. If the ANOVA demonstrated a significant effect, post hoc comparisons were made pairwise using Fisher's least significant difference test. A p value of ≤ 0.05 was considered significantly different. Table S2 . Primers used in real-time PCR Gene name sense antisense 
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VLCAD 5'-ATGCAGTCGGCTCGGATGACCC-3' 5'-TGAGAAATTGTGCCTGTTCTTC-3' MCAD 5'-CTAACCCAGATCCTAAAGTACCCG-3' 5'-GGTGTCGGCTTCCA AATGA-3' CPT1b 5'-GAGTTCTCGATGGCTTTCCG-3' 5'-GACAGGACACTGTGTGGGTGAG-3' COX-1 5'-TGAAACCCCCAGCCATAAC-3' 5'-CCAGCGGGATCAAAGAAAG-3' COX-3 5'-CATCGTCTCGGAAGTATTTTT-3' 5'-ATTAGTAGGGCTTGATTTATGTGG-3' ERRα 5'-TGGAGCGGGAGGAGTACGTC-3' 5'-CAGCCTCAGCATCTTCAATGTG-3'
